Total Funding
38
13
Total FundingSeries A raised
Growth Score
-3 pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
630316
Otologic Pharmaceutics, Inc. is a development stage pharmaceutical company formed specifically to commercialize promising technologies.
Clayton I. Duncan: Chairman and Chief Executive OfficerPast Role: Sphinx Pharmaceuticals, CEO
David Karlman: Co-founder , CEO & Chairman
About the Company
Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders.
OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue to
work to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss.
